Allergy Therapeutics (GB:AGY) has released an update.
Allergy Therapeutics has announced its participation in the EAACI Congress 2024, where it will present significant research findings from its portfolio, including positive results from its Phase III G306 trial for a grass pollen allergy treatment and early-stage results for a novel peanut allergy vaccine candidate. The company’s presence at the congress underscores its dedication to advancing allergy treatments, with a focus on innovative immunotherapy approaches. No new price-sensitive information is expected to be disclosed during the event.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
